Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome

Kidney International

Volumn 92, Issue 1, 2017, Pages 248-257

  Sinha, Aditi ^a   Gupta, Aarti ^a   Kalaivani, Mani ^a   Hari, Pankaj ^a   Dinda, Amit K ^a   Bagga, Arvind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

calcineurin inhibitor; focal segmental glomerulosclerosis; minimal change disease

Indexed keywords

CREATININE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CHILD; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREND STUDY; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; INDIA; INFANT; KAPLAN MEIER METHOD; NEPHROTIC SYNDROME; PRESCHOOL CHILD; RECURRENT DISEASE; TIME FACTOR;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIA; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85015278737     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.01.019     Document Type: Article

References (55)

1. Zagury, A., Oliveira, A.L., Montalvão, J.A., et al. Steroid-resistant idiopathic nephrotic syndrome in children: long-term follow-up and risk factors for end-stage renal disease. J Bras Nefrol 35 (2013), 191–199.
2. Straatmann, C., Ayoob, R., Gbadegesin, R., et al. Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatr Nephrol 28 (2013), 1235–1241.
3. Gipson, D.S., Chin, H., Presler, T.P., et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21 (2006), 344–349.
4. Kidney Disease Improving Global Outcomes (KDIGO) Workgroup on clinical practice guideline for glomerulonephritis. Methods for guideline development. Kidney Int Suppl 2 (2012), 243–251.
5. Colquitt, J.L., Kirby, J., Green, C., et al. The clinical effectiveness and cost effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess 11 (2007), 1–93.
6. Troyanov, S., Wall, C.A., Miller, J.A., et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16 (2005), 1061–1068.
7. Gulati, A., Sinha, A., Gupta, A., et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82 (2012), 1130–1135.
8. Choudhry, S., Bagga, A., Hari, P., et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53 (2009), 760–769.
9. Hodson, E.M., Willis, N.S., Craig, J.C., Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev, 11, 2010, CD003594.
10. Ponticelli, C., Rizzoni, G., Edefonti, A., et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43 (1993), 1377–1384.
11. Lieberman, K.V., Tejani, A., A randomized double-blind placebo controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7 (1996), 56–63.
12. Cattran, D.C., Appel, G.B., Hebert, L.A., et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56 (1999), 2220–2226.
13. Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Steroid-resistant nephrotic syndrome in children. Kidney Int. Suppl 2 (2012), 172–176.
14. Samuel, S., Bitzan, M., Zappitelli, M., et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am J Kidney Dis 63 (2014), 354–362.
15. Indian Society of Pediatric Nephrology, Gulati, A., Bagga, A., Gulati, S., et al. Management of steroid resistant nephrotic syndrome. Indian Pediatr 46 (2009), 35–47.
16. Sinha, A., Sharma, A., Mehta, A., et al. Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol 23 (2013), 41–46.
17. Hamasaki, Y., Yoshikawa, N., Nakazato, H., et al., for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol 28 (2013), 765–771.
18. Roberti, I., Vyas, S., Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 25 (2010), 1117–1124.
19. Bagga, A., Hari, P., Moudgil, A., Jordan, S.C., Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42 (2003), 1114–1120.
20. Afzal, K., Bagga, A., Menon, S., et al. Treatment with mycophenolate mofetil and prednisolone for steroid dependent nephrotic syndrome. Pediatr Nephrol 22 (2007), 2059–2065.
21. Fujinaga, S., Ohtomo, Y., Hirano, D., et al. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72 (2009), 268–273.
22. Gellermann, J., Querfeld, U., Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19 (2004), 101–104.
23. Barletta, G.M., Smoyer, W.E., Bunchman, T.E., et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 18 (2003), 833–837.
24. Al-Akash, S., Al-Makdama, A., Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med 25 (2005), 380–384.
25. Dorresteijn, E.M., Kist-van Holthe, J.E., Levtchenko, E.N., et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23 (2008), 2013–2020.
26. Gellermann, J., Weber, L., Pape, L., et al. Gesellschaft für Pädiatrische Nephrologie (GPN). Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24 (2013), 1689–1697.
27. de Mello, V.R., Rodrigues, M.T., Mastrocinque, T.H., et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephritic syndrome. Pediatr Nephrol 25 (2010), 453–460.
28. Li, Z., Duan, C., He, J., et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 25 (2010), 883–888.
29. Gipson, D.S., Trachtman, H., Kaskel, F.J., et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80 (2011), 868–878.
30. Nikibakhsh, A.A., Mahmoodzadeh, H., Karamyyar, M., et al. Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. Int J Nephrol, 2011, 2011, 930965.
31. Jang, H.R., Jung, H.W., Lee, Y.J., et al. Combination treatment with corticosteroid, cyclosporine A, and mycophenolate in refractory nephrotic syndrome. Clin Nephrol 75 (2011), 511–517.
32. Hibino, S., Uemura, O., Nagai, T., et al. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol. Pediatr Int 57 (2015), 85–91.
33. Gellermann, J., Ehrich, J.H., Querfeld, U., Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27 (2012), 1970–1978.
34. Sinha, A., Bhatia, D., Gulati, A., et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30 (2015), 96–106.
35. Fujinaga, S., Ohtomo, Y., Umino, D., et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22 (2007), 71–76.
36. Plank, C., Kalb, V., Hinkes, B., et al., for Arbeitgemeinschaft für Pädiatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 23 (2008), 1483–1493.
37. Garin, E.H., Orak, J.K., Hiott, K.L., Sutherland, S.E., Cyclosporine therapy for steroid-resistant nephritic syndrome. A controlled study. Am J Kidney Dis 142 (1988), 985–988.
38. Yang, E.M., Lee, S.T., Choi, H.J., et al. Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula. World J Pediatr 12 (2016), 60–65.
39. Ramachandran, R., Kumar, V., Rathi, M., et al. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 29 (2014), 1918–1924.
40. Nickavar, A., Safarzadeh, A.E., Sotoudeh, K., et al. Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children. Iran J Kidney Dis 6 (2012), 346–349.
41. Ulinski, T., Dubourg, L., Saïd, M.H., et al. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20 (2005), 482–485.
42. Okada, M., Sugimoto, K., Yagi, K., et al. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49 (2007), 933–937.
43. Lee, K.W., Mak, R., An update review of therapeutic regimens for steroid resistant idiopathic nephrotic syndrome. HK J Paediatr 5 (2000), 70–75.
44. Report of the International Study of Kidney Disease in Children: Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 101 (1982), 514–518.
45. Nakanishi, K., Iijima, K., Ishikura, K., et al., Japanese Study Group of Renal Disease in Children. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 8 (2013), 756–762.
46. Tong, K., Mao, J., Fu, H., et al. The value of monitoring the serum concentration of mycophenolate mofetil in children with steroid-dependent/frequent relapsing nephrotic syndrome. Nephron 132 (2016), 327–334.
47. Hackl, Á., Cseprekál, O., Gessner, M., et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference?. Ther Drug Monit 38 (2016), 274–279.
48. Tellier S, Dallocchio A, Guigonis V, et al. Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome [e-pub ahead of print]. Clin J Am Soc Nephrol. doi: 10.2215/CJN.00320116. Accessed January 1, 2017.
49. Hibino, S., Nagai, T., Yamakawa, S., et al. Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. Clin Exp Nephrol 21 (2017), 152–158.
50. Sobiak, J., Resztak, M., Ostalska-Nowicka, D., et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 77 (2015), 189–196.
51. Schulz, K.F., Altman, D.G., Moher, D., the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMC Med, 8, 2010, 18.
52. Schwartz, G.J., Muñoz, A., Schneider, M.F., et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20 (2009), 629–637.
53. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2004), 555–576.
54. World Health Organization. Growth reference 5–19 years. Available at: www.who.int/growthref/tools/en. Accessed July 31, 2016.
55. Gulati, A., Sinha, A., Sreenivas, V., et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6 (2011), 63–69.